Paris, July 12th, 2011. CARMAT (FR0010907956, ALCAR), the designer and developer of the world's
most advanced total artificial heart, and Bull (via its subsidiary Amesys, a leader in mission-critical
system architecture) today announced their agreement on the supply of a power system.
Under the terms of the agreement, Amesys will develop a portable system that will enable patients
to move around independently and safely in their daily activities. The user-friendly equipment will
allow the patient to live at home and travel around. This system will be available by early 2012, in
time for the hospital-to-home discharge of the first clinical-phase recipients of the CARMAT heart.
"This agreement with Bull will enable the first patients to return home under good conditions",
emphasized CARMAT CEO Marcello Conviti. "The patient's quality of life has always been a crucial
parameter in CARMAT's development philosophy".
"We are delighted with this collaboration and CARMAT's renewed confidence. Our technical rigour
and expertise in mission-critical systems are at CARMAT's full disposal", added Olivier Jolland (Chief
Operating Officer at Amesys). "We shall have to find a balance between mobility, autonomy and
maximum reliability for the CARMAT system", he added.
CARMAT offers a response to a major public health issue associated with heart disease, the world’s
leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over
20 million patients in developed countries. By pursuing the development of its total artificial heart,
CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of
thousands of people suffering from heart failure
The Bull subsidiary Amesys has already provided CARMAT with monitoring equipment that will be
used in hospital, during the post-surgery phase and for follow-up visits. These specific solutions call
on Amesys' acknowledged skills in the integration and management of mission-critical systems
projects that combine high-reliability electronic and mechanical modules.
Bull is an IT company dedicated to helping private- and public-sector organizations optimize the architecture,
operations and financial return of their business-critical information system. Bull focuses on open and secure systems
and is the only European-based company offering expertise in all the key links in the IT value chain
For more information: www.bull.fr
About CARMAT: CARMAT, the world’s most advanced total artificial heart project.
The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT aims is
to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death:
chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in developed countries. By
pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart
transplants for the tens of thousands of people suffering from advanced heart failure.
The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known
throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the
technological expertise of EADS, world aerospace leader.
Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological
functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the
lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an
unparalleled quality of life.
A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been
granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.
Strongly committed, prestigious founders and shareholders: Truffle Capital (the leading European venture capital
firm), EADS, the Foundation Alain Carpentier and the thousands of institutional and individual shareholders who have
placed their trust in CARMAT.
For more information: www.carmatsas.com
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or
subscribe to, shares in Carmat ("the Company") in any country. This press release contains forward-looking statements that relate to the Company’s
objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and
involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing
its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological
developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and
other risks and uncertainties described, in particular, in the Company’s Document de Référence registered with the French Autorité des marches
financiers (“AMF”) on 27 April 2011 under number R. 11 - 017 together with the Note d’Opération approved by the AMF under visa number 11-108
on 11 July 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Director, Marketing & Investor Relations
Tel. : +33 (0)1 39 45 64 50
Tel.: +33 (0)6 85 52 84 84
Corporate communications/ press relations
Tel.: +33 (0)1 42 68 86 43